Overview
Description
Bavarian Nordic A/S is a biotechnology and pharmaceutical company headquartered in Hellerup, Denmark. The company primarily focuses on the development, manufacturing, and commercialization of vaccines for infectious diseases and immunotherapy treatments for cancer. Notably, Bavarian Nordic is recognized for its breakthrough work in developing vaccines against smallpox, Ebola, and other emerging infectious diseases, contributing significantly to global public health initiatives. With a robust product pipeline and a commitment to research and innovation, Bavarian Nordic plays a crucial role in the biotechnology sector, impacting both healthcare and national security through its vaccine offerings. The company's collaborations with governments, health organizations, and fellow biotech firms underscore its importance in the pharmaceutical landscape as a prominent developer of next-generation vaccines.
About
CEO
Dr. Paul John Chaplin MSc, Ph.D.
Employees
1354
Address
Philip Heymans Alle 3
Hellerup, 2900
Hellerup, 2900
Phone
45 33 26 83 83
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Denmark
MIC code
XCSE